Technological Advancements Driving the Drug Discovery Technologies Market; Emerging Markets to Reach $23.6 Billion in 2019
(PRWEB) April 02, 2015 -- Wellesley, Mass., April 2, 2015 – BCC Research (http://www.bccresearch.com) reveals in its new report on drug discovery technologies that notable advances in technology have been influencing all aspects of drug discovery and development in the past three decades. These include identification of areas for research through increasing the value of new commercial drugs. The requirement to collect and scientifically analyze data of growing intricacy is also on the rise at each step of the drug discovery process.
In 2013, North America had sales of around $15 billion in the global market for drug discovery technologies, which is projected to grow to $32 billion in 2019, rising at a 12.6% compound annual growth rate (CAGR) from 2014 through 2019. Europe could reach about $23.9 billion in 2019 from about $12.4 billion in 2013. Emerging markets generated nearly $12.2 billion in 2013, which can reach $23.6 billion in 2019, growing at a CAGR of 10.5% from 2014 through 2019.
Technologies such as metabolomics, combinatorial chemistry, systems biology and nanotechnology are increasingly being utilized in drug discovery for better and superior results. These technologies – in combination with genomics, proteomics, cell-based assays and so forth – are expected to transform the drug discovery process, which is the most time- and cost-consuming step in the entire drug development lifecycle.
“Drug discovery technologies have a broad range, but these are incomplete without reference to the bioanalytical instruments that are used in many of the drug discovery techniques,” says BCC Research analyst Shalini S Dewan. “Major advancements in chromatographs, mass spectrometers, electrophoresis systems, microscopes, image recognition and particle characterization and other tools and instruments have directly and indirectly influenced the progress in the drug discovery technologies.”
Today, the pharmaceutical and biopharmaceutical industries rely on technologies such as high-throughput screening (HTS), proteomics, genomics, assays and so forth for the discovery of targets for drug discovery. These technologies and related products help speed up the discovery process along with providing easier means to identify correct targets/hits among numerous false hits, simpler validation and, eventually, high-end development processes.
Drug Discovery Technologies summarizes the market movement and innovations in the drug discovery technologies industry and emphasizes the requirement for integrated technological innovations for correct target identification. Forecasting is carried out for 2014 through 2019, analyzing for the regions of North America (the U.S. and Canada), Europe and emerging markets.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at [email protected].
About BCC Research
BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key market participants. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Recently selected as the world’s greatest market research company, BCC Research is a unit of Eli Global, LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email [email protected].
Steven Cumming, BCC Research, http://www.bccresearch.com, +1 (781) 489-7301 Ext: 632, [email protected]
Share this article